taletrectinib
Phase 2- Indications
- ROS1-positive non-small cell lung cancer
Company intelligence / Profile preview
AnHeart Therapeutics
New York, New York, United States
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
AnHeart's lead asset taletrectinib showed promising results in ROS1-positive NSCLC patients, receiving Breakthrough Therapy Designation from both the US FDA and China NMPA. The company was conducting pivotal Phase 2 trials (TRUST-II globally and TRUST in China) for taletrectinib in ROS1-positive NSCLC patients.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Daiichi SankyoInnovent BiologicsNippon KayakuNewG Lab
Beyond the preview
Go deeper on AnHeart Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AnHeart Therapeutics.